Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive, PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab in patients with Adenocarcinoma of the Gastroesophageal Junction.
This statement is based on a regulatory approval from the Health Canada:
KEYTRUDA (pembrolizumab), in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy,is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumours express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by a validated test.